15 research outputs found

    Scaling precipitation extremes with temperature in the Mediterranean: past climate assessment and projection in anthropogenic scenarios

    Get PDF

    L’acquisition des adverbiaux temporels en français Ă©crit chez l’enfant sourd : premiers rĂ©sultats comportementaux

    No full text
    International audienceAcquisition of temporal adverbials in written French in the deaf child: behavioral evidences. The purpose of this paper is a pilot study on the acquisition of temporal adverbials in written French in the deaf child. The conceptualization of cognitive and linguistic notions of temporality is a long developmental process in normo-typical children, and even more in deaf children. Owing to their hearing impairment and / or difficulty in language access, deaf children experience great difficulties to master the expression of temporality in French Sign Language (LSF) and written French. In order to understand the phenomenon and propose the first results on the acquisition and development of temporal adverbials, we created 3 reception tasks and 1 production task. These tasks varied in complexity of temporal adverbials used (3 semantic anchoring categories: anaphoric, deictic, frequential; 3 semantic operation categories: anteriority, identity, posteriority). We also compared skills according to the children's ILF (Indice de Fonctionnement Linguistique, i.e. Linguistic Performing Index: an index providing more objective benchmarks of their language capacity. While the data collected do not show IFL effect, they attest the more complex understanding of temporal adverbials in a multi-referential framework. These first results extend the knowledge on the development of temporality in French in deaf children.Cet article prĂ©sente les rĂ©sultats d’une Ă©tude pilote qui a pour objectif d’évaluer l’acquisition d’une composante en particulier du langage, la temporalitĂ©, chez des enfants sourds du primaire et du collĂšge. Ces derniers, de par leur dĂ©ficience auditive et/ou difficultĂ© d’accĂšs au langage, prĂ©sentent de grandes difficultĂ©s pour maĂźtriser l’expression de la temporalitĂ© en Langue des Signes Française (LSF) et en Français Ă©crit. Afin de pallier l’absence de donnĂ©es prĂ©cises sur l’acquisition de la composante temporelle en français Ă©crit, nous avons proposĂ© trois Ă©preuves de comprĂ©hension et une Ă©preuve de production centrĂ©es sur les adverbiaux temporels. Ces Ă©preuves ont Ă©tĂ© Ă©laborĂ©es selon une complexitĂ© supposĂ©e croissante, et reposant sur des distinctions sĂ©mantiques entre adverbiaux temporels. Nous avons Ă©galement comparĂ© les compĂ©tences en fonction de l’Indice de Fonctionnement Linguistique (IFL) des enfants, indice objectivant leur potentiel langagier. Si les donnĂ©es collectĂ©es ne permettent pas d’observer d’effet de l’IFL, elles attestent de la complexitĂ© Ă  comprendre pour un enfant sourd des adverbiaux temporels dans un cadre multi-rĂ©fĂ©rentiel

    Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients

    No full text
    With balanced safety-efficacy profile, letermovir anti-cytomegalovirus (CMV) prophylaxis is used in hematopoietic stem cell transplant recipients (HSCTR). We assessed feasibility and usefulness of letermovir therapeutic drug monitoring (TDM) in HSCTR. We performed a prospective observational study on letermovir-TDM including 40 consecutive adult CMV-seropositive allogeneic-HSCTR who received orally (PO) administered letermovir. Minimal blood concentrations of letermovir (Ctrough) were measured on days 3 and 7 postletermovir initiation and weekly thereafter. Letermovir-Ctrough remained stable during the first 70 days post-HSCT at a median of 286 Όg/L (interquartile range, 131 to 591 ÎŒg/L), with large interpatient/intrapatient variability. No associations between breakthrough clinically significant CMV infection or detectable CMV DNAemia and letermovir-Ctrough were observed. Patients with letermovir-associated adverse events had higher letermovir-Ctrough than patients without (400 versus 266 Όg/L, P = 0.02). Letermovir-Ctrough was similar in patients with or without gastrointestinal symptoms (280 versus 300 Όg/L, P = 0.49). Acute grade ≄2 GvHD was associated with higher letermovir-Ctrough (479 versus 248 Όg/L, P = 0.001), including gastrointestinal GvHD (499 versus 263 Όg/L, P = 0.004). Concomitantly administered posaconazole and cyclosporine were associated with higher letermovir-Ctrough (707 versus 259 Όg/L, P < 0.001 and 437 versus 248 Όg/L, P = 0.01, respectively). In multivariable analysis, both posaconazole (odds ratio [OR], 4.9; 95% confidence interval [CI], 2.4 to 9.7; P < 0.0001) and cyclosporine-adjusted letermovir dose at 240 mg daily (OR, 3.5; 95% CI, 1.4 to 9.0; P = 0.01) were independently associated with higher letermovir-Ctrough. In conclusion, administration of PO letermovir led to measurable and relatively stable letermovir-Ctrough, without noticeable associations with clinical efficacy. Letermovir exposure was not affected by gastrointestinal symptoms, but with posaconazole and cyclosporine administration. Associations between letermovir and concomitantly administered agents and adverse events warrant additional clinical studies
    corecore